文献速递母胎医学产科

胎儿水肿中下一代测序较标准产前诊断的增量检出率:FIND研究

Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-01-01

该前瞻性队列研究纳入28例核型或CMA阴性、经三人组ES检测的产前非免疫性胎儿水肿(NIHF)病例,并结合系统综述(21项研究、306例)进行荟萃分析。结果显示,ES在全部NIHF中的合并增量检出率为29%(95%CI 24-34%),孤立性NIHF为21%(95%CI 13-30%),合并其他结构异常者为39%(95%CI 30-49%)。

要点

  • ES在核型/CMA阴性的NIHF中增量检出率约29%。
  • 合并其他结构异常时检出率更高(39%)。
  • RASopathies是最常见遗传病因(30.3%)。

核心结论

  • 在核型或CMA阴性的孤立性和非孤立性NIHF中,均应考虑产前下一代测序。
  • 鉴于潜在综合征诊断范围广且产前表型异质,外显子或全基因组测序可能比靶向基因panel更合适。

研究设计与样本

  • 前瞻性队列研究(PAGE研究扩展组)纳入28例产前诊断NIHF、核型或CMA阴性后行三人组ES的病例。
  • 结合系统综述(检索MEDLINE、EMBASE、CINAHL和ClinicalTrials.gov,2000年1月至2020年10月)进行荟萃分析,最终纳入21项研究、306例。

主要发现

  • 扩展PAGE队列中,ES较CMA/核型的额外诊断率在全部NIHF为25.0%(7/28),孤立性NIHF为21.4%(3/14),非孤立性NIHF为28.6%(4/14)。
  • 荟萃分析中,合并增量检出率在全部NIHF为29%(95%CI 24-34%;P<0.00001;I2=0%),孤立性NIHF为21%(95%CI 13-30%;P<0.00001;I2=0%),合并其他结构异常者为39%(95%CI 30-49%;P<0.00001;I2=1%)。
  • 合并其他结构异常组中,先天性肢体挛缩是最常见的与致病性变异相关的额外结构异常,占17.3%(19/110)。
  • 增量检出率根据水肿严重程度(两个 vs 三个或更多腔隙受累)无显著差异。
  • 最常见遗传病为RASopathies,占致病性变异病例的30.3%(27/89),其中最常见为PTPN11变异(44.4%;12/27)。

关键数值与推荐

  • 系统综述纳入标准:(i)至少2例NIHF接受测序;(ii)基于产前超声表型启动检测;(iii)CMA或核型结果阴性。
  • 增量诊断产出评估分组:全部NIHF、孤立性NIHF、NIHF合并其他胎儿结构异常、按严重程度分组的NIHF。

临床怎么用

  • 对核型或CMA阴性的孤立性和非孤立性NIHF,应考虑产前外显子或全基因组测序。
  • 临床路径开发中应将产前下一代测序纳入NIHF的评估。

局限性

  • 扩展PAGE队列样本量较小(28例)。
  • 荟萃分析中部分亚组病例数有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the incremental yield of exome sequencing (ES) over chromosomal microarray analysis (CMA) or karyotyping in prenatally diagnosed non-immune hydrops fetalis (NIHF). METHODS: A prospective cohort study (comprising an extended group of the Prenatal Assessment of Genomes and Exomes (PAGE) study) was performed which included 28 cases of prenatally diagnosed NIHF undergoing trio ES following negative CMA or karyotyping. These cases were combined with data from a systematic review of the literature. MEDLINE, EMBASE, CINAHL and ClinicalTrials.gov databases were searched electronically (January 2000 to October 2020) for studies reporting on the incremental yield of ES over CMA or karyotyping in fetuses with prenatally detected NIHF. Inclusion criteria for the systematic review were: (i) at least two cases of NIHF undergoing sequencing; (ii) testing initiated based on prenatal ultrasound-based phenotype; and (iii) negative CMA or karyotyping result. The incremental diagnostic yield of ES was assessed in: (i) all cases of NIHF; (ii) isolated NIHF; (iii) NIHF associated with an additional fetal structural anomaly; and (iv) NIHF according to severity (i.e. two vs three or more cavities affected). RESULTS: In the extended PAGE study cohort, the additional diagnostic yield of ES over CMA or karyotyping was 25.0% (7/28) in all NIHF cases, 21.4% (3/14) in those with isolated NIHF and 28.6% (4/14) in those with non-isolated NIHF. In the meta-analysis, the pooled incremental yield based on 21 studies (306 cases) was 29% (95% CI, 24-34%; P < 0.00001; I2 = 0%) in all NIHF, 21% (95% CI, 13-30%; P < 0.00001; I2 = 0%) in isolated NIHF and 39% (95% CI, 30-49%; P < 0.00001; I2 = 1%) in NIHF associated with an additional fetal structural anomaly. In the latter group, congenital limb contractures were the most prevalent additional structural anomaly associated with a causative pathogenic variant, occurring in 17.3% (19/110) of cases. The incremental yield did not differ significantly according to hydrops severity. The most common genetic disorders identified were RASopathies, occurring in 30.3% (27/89) of cases with a causative pathogenic variant, most frequently due to a PTPN11 variant (44.4%; 12/27). The predominant inheritance pattern in causative pathogenic variants was autosomal dominant in monoallelic disease genes (57.3%; 51/89), with most being de novo (86.3%; 44/51). CONCLUSIONS: Use of prenatal next-generation sequencing in both isolated and non-isolated NIHF should be considered in the development of clinical pathways. Given the wide range of potential syndromic diagnoses and heterogeneity in the prenatal phenotype of NIHF, exome or whole-genome sequencing may prove to be a more appropriate testing approach than a targeted gene panel testing strategy. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mone F, Eberhardt RY, Hurles ME, et al. Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis. Ultrasound Obstet Gynecol. 2021. PMID: 33847422. doi:10.1002/uog.23652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。